TY - JOUR
T1 - DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases
AU - Handelsman, Yehuda
AU - Anderson, John E.
AU - Bakris, George L.
AU - Ballantyne, Christie M.
AU - Beckman, Joshua A.
AU - Bhatt, Deepak L.
AU - Bloomgarden, Zachary T.
AU - Bozkurt, Biykem
AU - Budoff, Matthew J.
AU - Butler, Javed
AU - Dagogo-Jack, Samuel
AU - de Boer, Ian H.
AU - DeFronzo, Ralph A.
AU - Eckel, Robert H.
AU - Einhorn, Daniel
AU - Fonseca, Vivian A.
AU - Green, Jennifer B.
AU - Grunberger, George
AU - Guerin, Chris
AU - Inzucchi, Silvio E.
AU - Jellinger, Paul S.
AU - Kosiborod, Mikhail N.
AU - Kushner, Pamela
AU - Lepor, Norman
AU - Mende, Christian W.
AU - Michos, Erin D.
AU - Plutzky, Jorge
AU - Taub, Pam R.
AU - Umpierrez, Guillermo E.
AU - Vaduganathan, Muthiah
AU - Weir, Matthew R.
N1 - Publisher Copyright:
© 2021
PY - 2022/2
Y1 - 2022/2
N2 - Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)—along with their associated risk factors—have overlapping etiologies, and two or more of these conditions frequently occur in the same patient. Many recent cardiovascular outcome trials (CVOTs) have demonstrated the benefits of agents originally developed to control T2D, ASCVD, or CKD risk factors, and these agents have transcended their primary indications to confer benefits across a range of conditions. This evolution in CVOT evidence calls for practice recommendations that are not constrained by a single discipline to help clinicians manage patients with complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. The ultimate goal for these recommendations is to be comprehensive yet succinct and easy to follow by the nonexpert—whether a specialist or a primary care clinician. To meet this need, we formed a volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM Practice Recommendations, a multispecialty consensus on the comprehensive management of the patient with complicated metabolic disease. The task force recommendations are based on strong evidence and incorporate practical guidance that is clinically relevant and simple to implement, with the aim of improving outcomes in patients with DCRM. The recommendations are presented as 18 separate graphics covering lifestyle therapy, patient self-management education, technology for DCRM management, prediabetes, cognitive dysfunction, vaccinations, clinical tests, lipids, hypertension, anticoagulation and antiplatelet therapy, antihyperglycemic therapy, hypoglycemia, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), ASCVD, HF, CKD, and comorbid HF and CKD, as well as a graphical summary of medications used for DCRM.
AB - Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)—along with their associated risk factors—have overlapping etiologies, and two or more of these conditions frequently occur in the same patient. Many recent cardiovascular outcome trials (CVOTs) have demonstrated the benefits of agents originally developed to control T2D, ASCVD, or CKD risk factors, and these agents have transcended their primary indications to confer benefits across a range of conditions. This evolution in CVOT evidence calls for practice recommendations that are not constrained by a single discipline to help clinicians manage patients with complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. The ultimate goal for these recommendations is to be comprehensive yet succinct and easy to follow by the nonexpert—whether a specialist or a primary care clinician. To meet this need, we formed a volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM Practice Recommendations, a multispecialty consensus on the comprehensive management of the patient with complicated metabolic disease. The task force recommendations are based on strong evidence and incorporate practical guidance that is clinically relevant and simple to implement, with the aim of improving outcomes in patients with DCRM. The recommendations are presented as 18 separate graphics covering lifestyle therapy, patient self-management education, technology for DCRM management, prediabetes, cognitive dysfunction, vaccinations, clinical tests, lipids, hypertension, anticoagulation and antiplatelet therapy, antihyperglycemic therapy, hypoglycemia, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), ASCVD, HF, CKD, and comorbid HF and CKD, as well as a graphical summary of medications used for DCRM.
KW - Atherosclerotic cardiovascular disease
KW - Chronic kidney disease
KW - Clinical practice
KW - Consensus recommendations
KW - Heart failure
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85121229430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121229430&partnerID=8YFLogxK
U2 - 10.1016/j.jdiacomp.2021.108101
DO - 10.1016/j.jdiacomp.2021.108101
M3 - Review article
C2 - 34922811
AN - SCOPUS:85121229430
SN - 1056-8727
VL - 36
JO - Journal of Diabetes and Its Complications
JF - Journal of Diabetes and Its Complications
IS - 2
M1 - 108101
ER -